@article {OJIMA829, author = {TOSHIYASU OJIMA and MIKIHITO NAKAMORI and MASAKI NAKAMURA and MASAHIRO KATSUDA and KEIJI HAYATA and TOMOYA KATO and JUNYA KITADANI and HIROTAKA TABATA and AKIHIRO TAKEUCHI and MAKOTO IWAHASHI and HIROKI YAMAUE}, title = {Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus}, volume = {36}, number = {2}, pages = {829--834}, year = {2016}, publisher = {International Institute of Anticancer Research}, abstract = {Background: The aim of this phase II study was to evaluate the feasibility of a neoadjuvant chemotherapy regimen consisting of divided-dose docetaxel and cisplatin, with 5-fluorouracil (NAC-DCF), for treatment of patients with stage II/III squamous cell carcinoma of the esophagus (SCCE). Patients and Methods: The NAC-DCF regimen, consisting of 2-h infusion of docetaxel at 35 mg/m2 on days 1 and 8, 4-h infusion of cisplatin at 12 mg/m2 on days 1-5, and continuous infusion of 5-fluorouracil at 600 mg/m2 on days 1-5, was administered. We compared NAC-DCF with conventional NAC-CF. Results: The DCF group comprised of 45 patients, and the CF group comprised of 28 patients. The incidence of grade 3/4 neutropenia was significantly higher in the DCF group (56\%) than in the CF group (0\%). Grade 2/3 pathological response was attained in a significantly higher percentage of patients in the DCF group (40\%) than in the CF group (11\%) (p=0.0153). Conclusion: This DCF regimen led to a high frequency of pathological responses among patients with advanced SCCE.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/36/2/829}, eprint = {https://ar.iiarjournals.org/content/36/2/829.full.pdf}, journal = {Anticancer Research} }